Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
Breast Cancer, Lung Cancer, Prostate Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring stage IV breast cancer, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer, recurrent breast cancer, stage IV prostate cancer, recurrent prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven metastatic breast, lung, or prostate cancer Measurable disease No untreated CNS metastases No symptomatic CNS metastases requiring escalating doses of corticosteroids Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age 65 and over Sex Not specified Menopausal status Not specified Performance status Karnofsky 70-100% Life expectancy Not specified Hematopoietic Absolute neutrophil count at least 1,500/mm^3 Hemoglobin at least 8.0 g/dL Platelet count at least 100,000/mm^3 Hepatic Bilirubin normal SGOT and/or SGPT no greater than 2.5 times upper limit of normal (ULN) with alkaline phosphatase no greater than ULN OR Alkaline phosphatase no greater than 4 times ULN with SGOT and SGPT no greater than ULN Renal Not specified Cardiovascular No history of cardiac arrhythmia No congestive heart failure No myocardial infarction within the past 6 months Other No prior severe hypersensitivity reaction to docetaxel or other drugs containing polysorbate 80 No allergy to macrolide antibiotics No grade 2 or greater peripheral neuropathy No concurrent serious or uncontrolled infection Able to read, write, and converse in English PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Recovered from prior chemotherapy Endocrine therapy See Disease Characteristics Radiotherapy Recovered from prior radiotherapy Surgery Not specified Other No concurrent CYP3A4-inducing or inhibiting medications or herbal remedies No concurrent grapefruit juice No concurrent ethanol
Sites / Locations
- Memorial Sloan-Kettering Cancer Center